Alembic Pharmaceuticals Limited — PPTs, 05-02-2026: Investor Presentation

Alembic Pharma reported strong Q3 FY26 results! Total revenue jumped 11% YoY to INR 1,876 Cr. India's branded business grew 6% to INR 652 Cr, while US Generics also increased 6% to INR 553 Cr, fueled by new launches. Ex-US Generics was a standout, hitting an all-time high with 36% YoY growth at INR 406 Cr. API business saw stable 2% growth.

EBITDA rose 14% YoY to INR 308 Cr (16% margin). Net Profit Before Tax (pre-exceptional) surged 33% YoY to INR 204 Cr (11% margin).

The company is focused on expanding its portfolio and market reach, with 9 new US products launched this fiscal year and 7 approvals in Q3. The US branded business expects to launch Pivya in Q4. R&D investment continues strong at 9% of revenue. Management sees future growth driven by new facilities, strategic expansions, and cost efficiency across segments.